

Index to Volume 11

The index to Volume 11 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *Clinical Pharmacy* as "index terms" after abstracts.) IPA covers all authored papers and editorials in

Clinical Pharmacy, as well as selected letters and news reports. The subject index also notes all regular columns and, under the respective column headings, the titles of items in the "News," "Therapy Consultation," "Letters," "Editorials," and "Book Reviews" sections. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January	1-92
February	93-204
March	205-280
April	281-374
May	375-454
June	455-570

Issue	Pages
July	571-656
August	657-742
September	743-822
October	823-904
November	905-988
December	989-1052

Subject Index

A

Absorption

anti-infective agents; intraperitoneal, CAPD, 246
metoclopramide hydrochloride; peritoneal dialysis, 174

Acetaminophen; fever; therapy, pediatrics, review, 1005

Acquired immunodeficiency syndrome

didanosine; therapy, FDA approvals, 4
566C80; *P. carinii* pneumonia, treatment IND, FDA approvals, 99
foscarnet sodium; cytomegalic inclusion disease therapy, FDA approvals, 4
ganciclovir; cytomegalic inclusion disease therapy, liver toxicity, 432
zidovudine; therapy, DUE criteria, 63

Adenosine; use; evaluation, criteria, 727

Administration; Food and Drug Administration; procedures, changes, new-drug approvals, 574

Adolescents

antihistamines; DUE criteria, therapy, extrapyramidal side effects, 553
antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553
benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553
parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553

Adrenergic agents, see Sympathomimetic agents

Adverse drug reactions report form, 85, 649

Advertising Index, 92, 204, 280, 374, 454, 570, 656, 742, 822, 904, 988, 1042

Aerosols; β agonists; regular vs. as-needed, asthma therapy, 877

Age; patients; home parenteral nutrition therapy, toxicity, 543

Agency for Health Care Policy and Research; protocols; pain therapy, 309, 391

AIDS; see **Acquired immunodeficiency syndrome**

Alcohols, cetyl; combination, colfosceril palmitate, tyloxapol; adult respiratory distress syndrome therapy, neonate, 880; use evaluation criteria, 355

Aldesleukin; marketing; FDA approvals, 669

Allergies; fentanyl; diffuse rash, transdermal patches, 222

Aluminum; blood levels; sucralate toxicity, deferoxamine therapy, 636

Amantadine; hyperprolactinemia; therapy, psychotropic therapy, 851

American Society of Hospital Pharmacists; protocols; antimicrobial prophylaxis, surgery, 483; globulin immune, i.v. therapy, 117

Amino acids

choline; cognition disorders therapy, FDA disapprovals, 467
marketing; cognition disorders therapy, FDA disapprovals, 467

provals, 467

Aminoglycosides; intraperitoneal; absorption, CAPD, 246

Aminophylline

availability; liquid, enteral administration, 428
use; evaluation, criteria, 1033

Amphotericin B

candidiasis; therapy, burns, infant, 883
use; evaluation, bladder irrigation, criteria, 809

Anabolic agents; steroids; hyperfibrinogenemia therapy, 968

Analgesics and antipyretics

acetaminophen; fever therapy, pediatrics, review, 1005
aspirin; fever therapy, pediatrics, review, 1005
fentanyl; adverse reactions, transdermal patches, 222; transdermal patches, 22

ibuprofen; fever therapy, pediatrics, review, 1005
morphine sulfate; Baxter Infusor, PCA, postoperative pain therapy, 342; intrathecal and i.v. PCA vs. PCA alone, postoperative pain, 958; toxicity, muscle spasticity, midazolam therapy, 57
pain; protocols, therapy, 309, 391

Anemia; dapsone; hemolytic, toxicity, therapy, 800

Anesthetics; toxicity; nausea and vomiting, abdominal surgery, 965

Anesthetics, local

lidocaine, combination, prilocaine; pain therapy, s.c. injection sites, 347
pain; protocols, therapy, 391

Angiotensin-converting enzyme inhibitors; labeling; warnings, risks, pregnancy, 467

Antiarrhythmic drugs, see **Cardiac drugs**

Anti-infective agents

dosage schedules; therapy, postantibiotic effect, 876
566C80; *P. carinii* pneumonia, treatment IND, FDA approvals, 99

surgery; prophylaxis, ASHP protocols, 483
toxicity; endocrine disorders, HIV infections, therapy, 705; postantibiotic effect, factors, 865

Antibiotics

dosage schedules; therapy, postantibiotic effect, 876
mechanism of action; postantibiotic effect, 865
toxicity; endocrine disorders, HIV infections, therapy, 705

vancomycin; intraperitoneal, absorption, CAPD, 246

Antibodies; monoclonal; antidiarrheal, DUE criteria, 257; sepsis therapy, 223; sepsis therapy, criteria, 255

Anticoagulants

heparin; vs. sodium chloride, i.v. lock flushing, 797
ticlopidine hydrochloride; FDA approvals, 99

toxicity; hemorrhage, dental surgery, 857
warfarin sodium; interactions, tetracycline, potentiation, prothrombin time, 806; toxicity, intramural hematoma of the small intestine, 632

Anticonvulsants

clonazepam; and preclampsia therapy, 236
ethosuximide and phenobarbital; clearance, peritone-

al dialysis, 1030

phenobarbital and ethosuximide; clearance, peritoneal dialysis, 1030

Antidepressants

depression; therapy, geriatrics, 96
fluvoxamine; therapy, review, 930
paroxetine; therapy, review, 930
sertraline hydrochloride; FDA approvals, 381; therapy, review, 930

Antidotes

charcoal activated and methylene blue; therapy, dapsone toxicity, 800
methylene blue and charcoal activated; therapy, dapsone toxicity, 800

Antiemetics

metoclopramide hydrochloride; pharmacokinetics, CAPD, 174
ondansetron hydrochloride; pharmacokinetics, therapy, cisplatin toxicity, 1026
scopolamine; transdermal patches, hyperemesis gravidarum therapy, 830

Antifungals

amphotericin B; bladder irrigation, DUE criteria, 809; candidiasis therapy, burns, infant, 883
fluconazole; candidiasis therapy, lack, burns, infant, 883
toxicity; endocrine disorders, HIV infections, therapy, 705

Antihistamines

astemizole; toxicity, cardiovascular, labeling, warnings, 825
diphenhydramine hydrochloride; therapy, fentanyl adverse reactions, 222

drug use; evaluations, criteria, therapy, extrapyramidal side effects, 553

terfenadine; toxicity, cardiovascular, labeling, warnings, 825

Anti-inflammatory agents

nabumetone; FDA approvals, 381
nonsteroidal; toxicity, ulcers, therapy, review, 690
oxaprozin; nonsteroidal, therapy, 591

Antipileptic agents

hyperfibrinogenemia; therapy, 968
pravastatin sodium; FDA approvals, 99; hypercholesterolemia therapy, review, 677

simvastatin; FDA approvals, 290

Antineoplastic agents

aldesleukin; FDA approvals, 669
cisplatin; toxicity, ondansetron therapy, pharmacokinetics, 1026

finasteride; FDA approvals, 825

idarubicin; acute nonlymphocytic leukemia therapy, 152

leukemia; acute, adult, therapy, review, 767

taxol; treatment IND, FDA approvals, 912

Antiparkinson agents; drug use; evaluation, criteria, therapy, extrapyramidal side effects, 553

Antivirals

- didanosine; AIDS therapy, FDA approvals, 4; DUE criteria, 885
- foscarnet sodium; cytomegalic inclusion disease therapy, AIDS, FDA approvals, 4
- ganciclovir; liver toxicity, cytomegalic inclusion disease therapy, AIDS, 432
- toxicity; endocrine disorders, HIV infections, therapy, 705
- zalcitabine; AIDS buyers groups, FDA actions, 385; marketing, FDA approvals, accelerated drug review policy, 747
- zidovudine; DUE criteria, 63
- zidovudine and zalcitabine; combined therapy, HIV infections, 747
- Anxiolytics, sedatives and hypnotics;** triazolam; labeling changes, package inserts, FDA approvals, 467; product withdrawal, United Kingdom, 9
- Atrial fibrillation;** therapy; toxicity, review, 714
- Asthma**
 - nabumetone; rheumatoid, therapy, FDA approvals, 381
 - oxaprozin; rheumatoid, therapy, 591
- ASHP Commission on Therapeutics;** protocols; antimicrobial prophylaxis, surgery, 483; i.v. globulin immune, 117
- Asians;** Koreans; phenylpropanolamine, toxicity, hypertension, lack, 168
- Aspirin**
 - ecclampsia; and preeclampsia therapy, 236
 - fever; therapy, pediatrics, review, 1005
- Astemizole;** toxicity; cardiovascular, labeling, warnings, 825
- Asthma**
 - β agonists; therapy, aerosols, dosage schedules, 877
 - sympathomimetic agents; β agonists, therapy, controversies, 13
- Atracurium besylate;** use; evaluation, criteria, 435
- Availability, drugs; see Drugs, availability**
- Azithromycin**
 - marketing; delay, Pfizer, 218; FDA approvals, 98
 - pharmacology, 137

B

Bacterial infections

- antibodies; antitendotoxin monoclonal, therapy, 223; antitendotoxin monoclonal, therapy, criteria, 255; antitendotoxin monoclonal, therapy, DUE criteria, 257
- anti-infective agents; prophylaxis, surgery, ASHP protocols, 483
- cefepoxime proxetil; bacterial, therapy, FDA approvals, 999
- cefprozil; therapy, FDA approvals, 295
- lomefloxacin hydrochloride; therapy, FDA approvals, 458
- temafloxacin hydrochloride; therapy, FDA approvals, 381
- Barbiturates;** pain; protocols, therapy, 391
- Basal ganglia diseases;** psychotherapeutic agents; toxicity, therapy, DUE criteria, 553
- Benzodiazepine antagonists;** flumazenil; FDA approvals, 287
- Benzodiazepines**
 - drug use; evaluation, criteria, therapy, extrapyramidal side effects, 553
 - overdose; toxicity, flumazenil therapy, 287
 - pain; protocols, therapy, 391
- Beractant;** use; evaluation, criteria, 357
- Bioavailability; see Drugs, availability**
- Biologicals;** approvals; FDA, 1991, 208
- Blood levels**
 - aluminum; sucralate toxicity, deferoxamine therapy, 636
 - ceftriaxone; i.m., concentrated, pediatrics, 961
 - cholesterol; and HDL monitoring, coronary disease, 378
 - ciprofloxacin; and milk levels, 352
 - ethosuximide and phenobarbital; decreased, peritoneal dialysis, 1030
 - fentanyl; transdermal patches, pain therapy, 22
 - ondansetron hydrochloride; pharmacokinetics, therapy, cisplatin toxicity, 1026
 - phenobarbital and ethosuximide; decreased, peritoneal dialysis, 1030
 - theophylline; aminophylline availability, enteral administration, 428
- Book Reviews;** 92, 277, 373, 565, 655, 742, 897, *Advances in Pain Research and Therapy, Volume 18: The Design of Analgesic Clinical Trials*, 92
- Applied Therapeutics: The Clinical Use of Drugs, Fifth*

Edition, 897

- The Biochemical Basis of Neuropharmacology, Sixth Edition*, 655
- Clinical Immunotoxicology*, 900
- Combined Modality Cancer Therapy: Radiation and Infusional Chemotherapy*, 565
- Data Collection Forms in Clinical Trials*, 373
- Drugs in Gastroenterology*, 565
- Guide to Clinical Trials*, 277
- Handbook of Basic Pharmacokinetics . . . including Clinical Applications, Fourth Edition*, 901
- Manual of Antibiotics and Infectious Diseases, Seventh Edition*, 742
- Neoplastic Diseases: Fundamentals of Clinical Oncology*, 901
- Pharmacokinetics and Pharmacodynamics, Volume 3: Peptides, Peptoids, and Proteins*, 277
- Books Received,** 198, 374, 454, 570, 655, 742, 904, 1042
- Bromocriptine;** hyperprolactinemia; therapy, psychotropic toxicity, 851
- Burns**
 - amphotericin B; candidiasis therapy, infant, 883
 - fluconazole; candidiasis therapy, lack, infant, 883

C

Calcium antagonists

- hyperfibrinogenemia; therapy, 968
- new drugs; advantages, 549
- nimodipine; cerebrovascular ischemia therapy, 350
- verapamil hydrochloride; pharmacokinetics, intact capsules vs. sprinkled on food, 539
- Calcium regulators;** pamidronate disodium; hypercalcemia therapy, FDA approvals, 220
- Cancer; see Antineoplastic agents**
- Cancer drugs; see Antineoplastic agents**
- Candidiasis**
 - amphotericin B; therapy, burns, infant, 883
 - fluconazole; therapy, lack, burns, infant, 883
- Capsules;** verapamil hydrochloride; intact vs. sprinkled on food, equivalency, pharmacokinetics, 539
- Carbamazepine;** concomitant therapy, 632
- Carcinoma;** aldesleukin; renal cell, therapy, FDA approvals, 669
- Cardiac drugs**
 - adenosine; DUE criteria, 727
 - antiarrhythmic agents; therapy, toxicity, review, 714
 - dobutamine; congestive heart failure, long-term therapy, 618
 - flecainide; interactions, implanted cardiac devices, 48
 - moricizine; interactions, implanted cardiac devices, 48
- Cefazolin sodium;** toxicity; seizures, intraventricular injections, 104
- Cefepoxime proxetil;** marketing; FDA approvals, 999
- Cefprozil;** marketing; FDA approvals, 295
- Ceftriaxone;** reconstitution; i.m., pharmacokinetics and toxicity, pediatrics, 961
- Cellulose;** hemorrhage; prophylaxis, dental surgery, anticoagulant toxicity, 857
- Central nervous system drugs;** cognition activators; FDA disapprovals, 467
- Cephalosporins**
 - cefazolin sodium; toxicity, seizures, intraventricular injections, 104
 - cefepoxime proxetil; FDA approvals, 999
 - cefprozil; FDA approvals, 295
 - ceftriaxone; concentrated, pharmacokinetics, toxicity, pediatrics, 961
 - intraperitoneal; absorption, CAPD, 246
- Cerebral ischemia;** nimodipine; therapy, 350
- Cerebrovascular disorders**
 - nimodipine; ischemic stroke therapy, 350
 - ticlopidine hydrochloride; prophylaxis, FDA approvals, 99; therapy, review, 603
- Charcoal activated;** and methylene blue; therapy, dapsone toxicity, 800
- Cholelitholytic agents;** ursodiol; pruritus therapy, biliary cirrhosis, 672
- Cholesterol;** tests, laboratory; and HDL monitoring, coronary disease, 378
- Choline;** marketing; cognition disorders therapy, FDA disapprovals, 467
- Ciprofloxacin hydrochloride;** body distribution; blood and milk levels, 352
- Cisplatin;** toxicity; ondansetron therapy, pharmacokinetics, 1026
- Clarithromycin**
 - marketing; FDA approvals, 98
 - pharmacology, 137
- Clearance; see Excretion**

Clinical Pharmacy

- acknowledgment to reviewers—October 1, 1991, to September 30, 1992, 1032
- instructions for submitting computer disks with revised manuscripts, 62
- procedure for submission of manuscripts to journals published by the American Society of Hospital Pharmacists, 60
- Clinical studies**
 - dobutamine; congestive heart failure, long-term therapy, 618
 - pravastatin sodium; hypercholesterolemia therapy, review, 677
- Cognition disorders;** therapy; amino acids, vitamins, marketing, FDA disapprovals, 467
- Colfosceril palmitate;** combination, alcohols, cetyl, tyloxapol; adult respiratory distress syndrome therapy, neonate, 880; use evaluation criteria, 355
- Collagen;** hemorrhage; microcrystalline, prophylaxis, dental surgery, anticoagulant toxicity, 857
- Combined therapy**
 - acetaminophen and aspirin; fever, pediatrics, review, 1005
 - aspirin and acetaminophen; fever, pediatrics, review, 1005
 - zalcitabine and zidovudine; HIV infections, FDA approvals, 747
 - zidovudine and zalcitabine; HIV infections, FDA approvals, 747
- Commentaries,** 350, 549, 714, 797, 876, 968
- Complexes**
 - Haemophilus b* oligosaccharide conjugate vaccines; equivalency, immunogenicity, pediatrics, 332
 - Haemophilus b* polysaccharide conjugate vaccines; equivalency, immunogenicity, pediatrics, 332
- Compliance;** patients; calcium antagonists therapy, 549
- Concentration**
 - antibiotics; postantibiotic effect, 865
 - ceftriaxone; i.m., pharmacokinetics, toxicity, pediatrics, 961
 - globulin immune; injections, administration rate, toxicity, 1022; reconstitution, dextrose vs. water for injection, 628
- Control, quality;** zalcitabine; problems, AIDS buyers groups, 385
- Coronary disease;** tests, laboratory; cholesterol and HDL monitoring, 378
- Correction Notices,** 14, 308, 585, 750, 829
- Advance's in the treatment of unstable angina pectoris** (Nov 1991, Therapy Review), 14
- American Academy of Pediatrics issues recommendations on treatment of Lyme disease** (Oct 1991, News), 14
- Clarithromycin and azithromycin:** New macrolide antibiotics (Feb 1992, Drug Review), 308
- Parenteral nutrition in pediatric patients** (May 1988, Therapy Review), 750
- Retreatment with digoxin immune Fab** (Nov 1991, Letters), 14
- Review of 1991 shows 30 new drugs, several important biologics cleared for marketing** (Mar 1992, News), 585
- Table of contents** (Aug 1992), 829
- Cost**
 - Haemophilus b* oligosaccharide conjugate vaccines; immunization, pediatrics, 332
 - Haemophilus b* polysaccharide conjugate vaccines; immunization, pediatrics, 332
 - zalcitabine; therapy, 747
- CP Continuing Education,** 77, 189, 261, 442, 559, 640, 731, 811, 892, 976, 1039
- Creams;** lidocaine, combination, prilocaine; anesthesia, pain, s.c. injection sites, 347
- Current Literature,** 87, 197, 273, 368, 448, 562, 652, 735, 819, 895, 978, 1040
- Cytomegalic inclusion disease**
 - foscarnet sodium; therapy, AIDS, FDA approvals, 4
 - ganciclovir; therapy, liver toxicity, AIDS, 432
- Cytotoxic agents; see Antineoplastic agents**

D

- Dapsone;** toxicity; hemolytic anemia, methemoglobinemia, therapy, 800
- ddl; see Didanosine**
- Deferoxamine mesylate;** therapy; aluminum overload, sucralate toxicity, CAPD, 636
- Depression**
 - serotonin reuptake inhibitors; therapy, review, 930
 - sertraline hydrochloride; therapy, FDA approvals, 381
 - therapy; geriatrics, 96

Devices

- Baxter Infusor; morphine PCA, postoperative pain therapy, 342
 implants; cardiac, interactions, antiarrhythmic agents, 48
 metrology; cups, spoons, droppers, drug overdose, 220
Dextrose; comparison, water for injection; globulin immune reconstitution, toxicity, 628
Diabetes mellitus
 electrolytes, combination, polyethylene glycol; gastric lavage, protocols, 751
 metoclopramide hydrochloride; pharmacokinetics, CAPD, 174
Dialysis; peritoneal; clearance, ethosuximide and phenobarbital, 1030; continuous ambulatory, anti-infective agents absorption, 246; metoclopramide pharmacokinetics, 174; sucralate, toxicity, aluminum overload, 636
Diazepam; eclampsia; and preeclampsia therapy, 236
Didanosine
 marketing; FDA approvals, 4
 use; evaluation, criteria, 885
Diluents; lidocaine; ceftriaxone, i.m., reconstitution, pediatric, 961
Diphenhydramine hydrochloride; allergies; therapy, fentanyl adverse reactions, 222
Diphtheria and tetanus toxoids and pertussis vaccines; marketing; FDA approvals, 290
Diuretics; hydrochlorothiazide; hypertension therapy, phenylpropanolamine effects, lack, 168
Dobutamine; heart failure; congestive, long-term therapy, 618
Dosage
 adenine; DUE criteria, 727
 alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; DUE criteria, 355
 aldesleukin, 669
 aminophylline; DUE criteria, 1033
 amphotericin B; DUE criteria, 809
 analgesics and antipyretics; fever therapy, pediatrics, review, 1005
 antibodies; monoclonal antiendotoxin, DUE criteria, 257
 antihistamines; DUE criteria, therapy, extrapyramidal side effects, 553
 anti-infective agents; intraperitoneal, absorption, CAPD, 246
 antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553
 azithromycin, 98, 137
 benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553
 beractant; DUE criteria, 357
 cefpodoxime proxetil, 999
 cefprozil, 295
 cisplatin; high, toxicity, ondansetron therapy, 1026
 clarithromycin, 98, 137
 didanosine, 4; DUE criteria, 885
 diphtheria and tetanus toxoids and pertussis vaccines; immunization, pediatrics, 290
 dobutamine; congestive heart failure, long-term therapy, 618
 doxazosin mesylate, 415
 ethosuximide and phenobarbital; clearance, peritoneal dialysis, 1030
 felodipine, 9
 fentanyl; adverse reactions, transdermal patches, 222
 flunazepam, 287
 foscarnet sodium, 4
Haemophilus b oligosaccharide conjugate vaccines; immunization, pediatrics, 332
Haemophilus b polysaccharide conjugate vaccines; immunization, pediatrics, 332
 idarubicin, 152
 interferon; review, 834
 interferon gamma-1b; review, 834
 lactase; lactose intolerance, reduced symptoms, 533
 lomefloxacin hydrochloride, 458; review, 753
 morphine sulfate; Baxter Infusor, PCA, postoperative pain therapy, 342
 nabumetone, 381
 omeprazole; ulcers, peptic esophagitis, DUE criteria, 177
 overdose; benzodiazepines, flumazenil therapy, 287; dapsone, toxicity, hemolytic anemia, methemoglobinemia, 800; measuring cups, spoons, droppers, toxicity, 220
 oxaprozin, 591
 pamidronate disodium, 220
 parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553
 phenobarbital and ethosuximide; clearance, peritone-

- al dialysis, 1030
 pravastatin sodium, 99; hypercholesterolemia therapy, review, 677
 quinapril hydrochloride, 220
 serotonin reuptake inhibitors; depression therapy, review, 930
 sertraline hydrochloride, 381
 simvastatin, 290
 skeletal muscle relaxants; DUE criteria, 435
 sumatriptan; DUE criteria, 972
 sumatriptan succinate; therapy, review, 919
 temafloxacin hydrochloride, 381; review, 753
 theophylline; DUE criteria, 1033
 ticlopidine hydrochloride, 99; review, 603
 ursodiol; pruritus therapy, biliary cirrhosis, 672
 zalcitabine, 747
 zidovudine; DUE criteria, 63
Dosage forms
 drug administration systems; measuring cups, spoons, droppers, overdose, 220
 fentanyl; transdermal patches, adverse reactions, 222; transdermal patches, pain therapy, 22
Dosage schedules
 β agonists; aerosols, regular vs. as-needed, asthma therapy, 877
 antibiotics; postantibiotic effect, 865; therapy, postantibiotic effect, 876
 anti-infective agents; prophylaxis, surgery, ASHP protocols, 483; therapy, postantibiotic effect, 876
 calcium antagonists; therapy, 549
 dobutamine; congestive heart failure, long-term therapy, 618
 nutrition; parenteral, chronic home therapy, toxicity, 543
 oxaprozin, 591
 triazolam; labeling changes, FDA approvals, 467
Doxacurium chloride; use; evaluation, criteria, 435
Doxazosin mesylate; pharmacology; review, 415
Drug administration
 alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; intratracheal, adult respiratory distress syndrome, neonate, 880
 γ -interferon; chronic granulomatous disease therapy, 834
 interferon gamma-1b; chronic granulomatous disease therapy, 834
 serotonin reuptake inhibitors; depression therapy, review, 930
 verapamil hydrochloride; equivalency, intact capsules vs. sprinkled on food, 539
Drug administration rate; globulin immune; i.v. infusion, concentration, toxicity, 1022
Drug administration routes
 β agonists; regular vs. as-needed, asthma, 877
 aminophylline; enteral administration, availability, 428
 anti-infective agents; prophylaxis, surgery, ASHP protocols, 483
 cefazolin sodium; intraventricular, toxicity, seizures, 104
 deferoxamine mesylate; intraperitoneal, i.v., aluminum overload therapy, 636
 fentanyl; transdermal patches, pain therapy, 22
 intraperitoneal; anti-infective agents, absorption, CAPD, 246
 mesalamine; rectal, inflammatory bowel disease therapy, 514
 methotrexate; intramuscular, ectopic pregnancy therapy, 529
 metoclopramide hydrochloride; i.p. vs. i.v. oral, pharmacokinetics, CAPD, 174
 morphine sulfate; intrathecal and i.v. PCA vs. PCA alone, postoperative pain therapy, 958
 olsalazine sodium; oral, inflammatory bowel disease therapy, 514
 roentgenographic agents; ionic, epidural, toxicity, inadvertent intrathecal injection, 105
 scopolamine; transdermal patches, hyperemesis gravidarum therapy, 830
Drug administration sites
 fentanyl; transdermal patches, adverse reactions, 222
 lidocaine, combination, prilocaine; anesthesia, pain, s.c. injections, 347
Drug administration systems
 Baxter Infusor; morphine PCA, postoperative pain therapy, 342
 devices; measuring cups, spoons, droppers, overdose, 220
Drug interactions
 antiarrhythmic agents and devices; cardiac implants, impaired functioning, 48
 azithromycin, 137
 cisplatin and ondansetron hydrochloride; pharmacokinetics, 1026
 clarithromycin, 137
 devices and antiarrhythmic agents; cardiac implants, impaired functioning, 48
 food and verapamil hydrochloride; equivalency, intact capsules vs. sprinkled, 539
 lomefloxacin hydrochloride; review, 753
 ondansetron hydrochloride and cisplatin; pharmacokinetics, 1026
 serotonin reuptake inhibitors; depression therapy, review, 930
 sucralate and tests; laboratory; occult blood, interference, 625
 temafloxacin hydrochloride; review, 753
 tests, laboratory and sucralate; occult blood, interference, 625
 tetracycline hydrochloride and warfarin sodium; potentiation, prothrombin time, 806
 verapamil hydrochloride and food; equivalency, intact capsules vs. sprinkled, 539
 warfarin sodium and tetracycline hydrochloride; potentiation, prothrombin time, 806
Drug Reaction Alerts, 87, 197, 273, 368, 448, 562, 652, 735, 819, 895, 978, 1040
Drugs
 new; marketing, FDA approvals, 1991, 208
 reconstitution; ceftriaxone, i.m., pharmacokinetics, toxicity, pediatrics, 961; globulin immune, dextrose vs. water for injection, 628
 selection; antimicrobial prophylaxis, surgery, ASHP protocols, 483
Drugs, adverse reactions, see **Toxicity**
Drugs, availability; aminophylline; liquid, enteral administration, 428
Drugs, body distribution
 ciprofloxacin hydrochloride; blood and milk levels, 352
 metoclopramide hydrochloride; peritoneal dialysis, 174
Drugs, investigational
 investigational new drugs; 566C80, *P. carinii* pneumonia, protocols, 99; taxol, ovarian neoplasms therapy, protocols, 912; zalcitabine, FDA actions, premarketing access, 385
 new-drug applications; approvals, changes, FDA processing, 574
Drug use
 evaluation; adenine, criteria, 727; aminophylline, theophylline, criteria, 1033; amphotericin B, bladder irrigation, criteria, 809; antiendotoxin monoclonal antibodies, criteria, 257; beractant, criteria, 357; didanosine, criteria, 885; Exosurf Neonatal, criteria, 355; omeprazole, criteria, 177; skeletal muscle relaxants, criteria, 435; sumatriptan, criteria, 972; therapy, extrapyramidal side effects, 553; zidovudine, criteria, 63
 fentanyl; diffuse rash, transdermal patches, 222
DUE Criteria, 63, 177, 257, 355, 435, 553, 727, 809, 885, 972, 1033
 adenine, 727
 agents for extrapyramidal adverse effects, 553
 amphotericin B bladder irrigation, 809
 antiendotoxin monoclonal antibodies (HA-1A and E5), 257
 beractant (Survanta), 357
 colfosceril (Exosurf Neonatal), 355
 didanosine, 885
 omeprazole, 177
 pancuronium bromide, vecuronium bromide, atracurium besylate, tubocurarine chloride, metocurine iodide, pipecuronium bromide, and doxacurium chloride, 435
 sumatriptan, 972
 theophylline (aminophylline), 1033
 zidovudine, 63
E
Eclampsia; therapy, 236
Editorial: Who should receive antiendotoxin monoclonal antibody therapy? 255
Electrolytes; combination, polyethylene glycol; gastric lavage, diabetes mellitus, protocols, 751
Endocrine diseases; therapy; HIV infections related, 705
Enzymes; lactase; lactose intolerance, reduced symptoms, 533
Epidemiology; leukemia; adult acute, therapy, review, 767
Epilepsy
 ethosuximide and phenobarbital; absence, clearance, peritoneal dialysis, 1030
 phenobarbital and ethosuximide; absence, clearance,

Annual Index

peritoneal dialysis, 1030
Equivalency
Haemophilus b oligosaccharide conjugate vaccines; immunogenicity, pediatrics, 332
Haemophilus b polysaccharide conjugate vaccines; immunogenicity, pediatrics, 332
 verapamil hydrochloride; pharmacokinetics, intact capsules vs. sprinkled on food, 539
Equivalency, generic; globulin immune; formulary selection, ASHP protocols, 117
Errors, medication; dosage; measuring devices, 220
Erythromycin; gastroparesis; therapy, effects, motilin, 917
Esophageal and gastric varices; β blockers; gastrointestinal hemorrhage prophylaxis, 337
Esophagitis; omeprazole; peptic, therapy, DUE criteria, 177
Ethosuximide and phenobarbital; clearance, peritoneal dialysis, 1030
Excretion
 ethosuximide and phenobarbital; clearance, peritoneal dialysis, 1030
 metoclopramide hydrochloride; clearance, CAPD, 174
 phenobarbital and ethosuximide; clearance, peritoneal dialysis, 1030

F

Felodipine; marketing; FDA approvals, 9
Fentanyl
 adverse reactions; diffuse rash, transdermal patches, 222
 patches transdermal; pain therapy, 22
Fever; analgesics and antipyretics; therapy, pediatrics, review, 1005
Finasteride; marketing; FDA approvals, 825
566C80; pneumonia; *P. carinii*, treatment IND, FDA approvals, 99
Flecainide; interactions; implanted cardiac devices, 48
Fluconazole; candidiasis; therapy, lack, burns, infant, 883
Flumazenil; marketing; FDA approvals, 287
Fluvoxamine; depression; therapy, review, 930
Food; interactions; verapamil, open vs. intact capsules, pharmacokinetics, 539
Food and Drug Administration (U.S.)
 approvals; aldesleukin marketing, 669; azithromycin, clarithromycin, marketing, 98; cefpodoxime marketing, 999; cefprozil marketing, 295; didanosine, foscarnet, marketing, 4; DTP vaccines marketing, 290; felodipine marketing, 9; finasteride marketing, 825; flumazenil marketing, 287; lomefloxacin marketing, 458; nabumetone marketing, 381; new-drug applications, changes, processing, 574; new drugs and biologicals, 1991, 208; pamidronate, marketing, 220; pravastatin, marketing, 99; quinapril, marketing, 220; sertraline marketing, 381; simvastatin marketing, 290; temafloxacin marketing, 381; ticlopidine, marketing, 99; triazolam labeling changes, package inserts, 467; zalcitabine, marketing, accelerated drug review policy, 747
 azithromycin; actions, toxicity reports, marketing delay, 218
 cognition activators; disapprovals, marketing, 467
 566C80; *P. carinii* pneumonia, treatment IND approvals, 99
 labeling; drug measuring devices, overdose, 220
 regulations; astemizole, terfenadine, warning labels, cardiovascular toxicity, 825; temafloxacin, toxicity, product withdrawal, 747
 taxol; treatment IND approvals, 912
 triazolam; actions, toxicity reports, 9
 zalcitabine; actions, AIDS buyers groups, quality problems, 385
Formularies; globulin immune; product selection, ASHP protocols, 117
Foscarnet sodium; marketing; FDA approvals, 4

G

Ganciclovir; toxicity; liver, cytomegalic inclusion disease therapy, AIDS, 432
Gastric lavage; electrolytes, combination, polyethylene glycol; diabetes mellitus, protocols, 751
Gastrointestinal drugs
 histamine H_2 antagonists; ulcer therapy, NSAID toxicity, review, 690
 mesalamine; inflammatory bowel disease therapy, 514

misoprostol; ulcer therapy, NSAID toxicity, review, 690
 olsalazine sodium; inflammatory bowel disease therapy, 514
 omeprazole; DUE criteria, 177; ulcer therapy, NSAID toxicity, review, 690
 sucralfate; interference, occult blood tests, 625; toxicity, aluminum overload, deferoxamine therapy, CAPD, 636
Gastrointestinal hemorrhage; β blockers; prophylaxis, cirrhosis, esophageal varices, 337
Gastroparesis; erythromycin; therapy, 917
Gelatin; sponges; hemorrhage prophylaxis, dental surgery, anticoagulant toxicity, 857
Geriatrics
 depression; therapy, 96
 pain; therapy, protocols, 391
Globulin immune
 reconstitution; dextrose vs. water for injection, toxicity, 628
 therapy; i.v., ASHP protocols, 117
 toxicity; side effects, concentrated injections, 1022
Granulomatous disease
 γ -interferon; chronic, therapy, 834
 interferon gamma-1b; chronic, therapy, 834
Guidelines, treatment, see Protocols

H

HA-1A
 see also **Nebacumab**
 sepsis; antiendotoxin monoclonal antibodies, therapy, 223
Haemophilus b oligosaccharide conjugate vaccines; immunization; equivalency, immunogenicity, pediatrics, 332
Haemophilus influenzae; immunization; conjugate vaccines, immunogenicity, pediatrics, 332
Headache; sumatriptan; therapy, DUE criteria, 972
Health care; home; parenteral nutrition, toxicity, 543
Heart failure; dobutamine; congestive, long-term therapy, 618
Heavy metal antagonists; deferoxamine mesylate; therapy, aluminum overload, sucralfate toxicity, CAPD, 636
Hematoma; warfarin sodium; toxicity, intramural, small intestine, 632
Hemorrhage; anticoagulants; toxicity, dental surgery, 857
Hemostatics; therapy; anticoagulant toxicity, dental surgery, 857
Heparin; flushes; toxicity, thrombocytopenia, thromboembolism, 797
HIV infections
 didanosine; therapy, DUE criteria, 885
 therapy; associated endocrine disorders, 705
 zalcitabine; therapy, Roche premarketing access programs, 385
 zalcitabine and zidovudine; combined therapy, FDA approvals, 747
 zidovudine and zalcitabine; combined therapy, FDA approvals, 747
Hoffmann-La Roche Pharmaceuticals; zalcitabine; investigational new drugs, premarketing access programs, 385
Hospitals; length of stay; nausea and vomiting, anesthetics toxicity, surgery, 965
Hydrochlorothiazide; hypertension; phenylpropanolamine effects, lack, 168
Hyperalimentation, see Nutrition; parenteral
Hypercalcemia; pamidronate disodium; therapy, neoplasms, FDA approvals, 220
Hypercholesterolemia
 pravastatin sodium; therapy, FDA approvals, 99; therapy, review, 677
 simvastatin; therapy, FDA approvals, 290
Hyperemesis gravidarum; scopolamine; transdermal patches, 830
Hyperfibrinogenemia; therapy, 968
Hyperprolactinemia; psychotherapeutic agents; toxicity, therapy, 851
Hypertension
 doxazosin mesylate; therapy, review, 415
 felodipine; therapy, FDA approvals, 9
 phenylpropanolamine hydrochloride; toxicity, lack, 168
 quinapril hydrochloride; therapy, FDA approvals, 220
Hypotensive agents
 doxazosin mesylate; review, 415
 eclampsia; and preeclampsia therapy, 236

felodipine; FDA approvals, 9
 quinapril hydrochloride; marketing, FDA approvals, 220

I

Ibuprofen; fever; therapy, pediatrics, review, 1005
Idarubicin; leukemia; nonlymphocytic, acute, therapy, 152
Immunization
 diphtheria and tetanus toxoids and pertussis; vaccines, FDA approvals, 290
Haemophilus influenzae; conjugate vaccines, immunogenicity, pediatrics, 332
 rabies; vaccines, human rabies immune globulin, 37
Immunogenicity
Haemophilus b oligosaccharide conjugate vaccines; equivalency, pediatrics, 332
Haemophilus b polysaccharide conjugate vaccines; equivalency, pediatrics, 332
Immunosuppressive agents; methotrexate; ectopic pregnancy therapy, 529
Immunotherapy
 globulin immune; i.v. therapy, ASHP protocols, 117; reconstitution, dextrose vs. water for injection, 628; toxicity, concentrated injections, bone marrow transplantation, 1022
 γ -interferon; chronic granulomatous disease, 834
 interferon gamma-1b; chronic granulomatous disease, 834
 nebacumab; sepsis, criteria, 255; sepsis, DUE criteria, 257
 sepsis; antiendotoxin monoclonal antibodies, 223
 Xomen-ES; sepsis, criteria, 255; sepsis, DUE criteria, 257
Implants; heart; interactions, antiarrhythmic agents, 48
Inflammatory bowel disease
 mesalamine; therapy, 514
 olsalazine sodium; therapy, 514
Injections
 cefazolin sodium; intraventricular, toxicity, seizures, 104
 ceftriaxone; i.m., concentrated, pharmacokinetics and toxicity, pediatrics, 961
 dobutamine; intravenous, congestive heart failure, long-term therapy, 618
 globulin immune; concentrated, i.v. infusion rate, toxicity, 1022; reconstitution, dextrose vs. water for injection, 628; i.v. therapy, ASHP protocols, 117
 heparin, comparison, sodium chloride; lock flushing, 797
 morphine sulfate; intrathecal and i.v. PCA vs. PCA alone, postoperative pain, 958
 pamidronate disodium; marketing, FDA approvals, 220
 patient-controlled analgesia; morphine, Baxter Infusor, postoperative pain therapy, 342
 roentgenographic agents; ionic, epidural, toxicity, inadvertent intrathecal administration, 105
 sodium chloride, comparison, heparin; lock flushing, 797
 subcutaneous; pain, lidocaine-prilocaine therapy, 347
Insomnia; triazolam; therapy, labeling, changes, package inserts, FDA approvals, 467
 γ -Interferon; granulomatous disease; chronic, therapy, review, 834
Interferon gamma-1b; granulomatous disease; chronic, therapy, review, 834
Irrigating solutions; amphotericin B; bladder, urinary anti-infectives, DUE criteria, 809

K

Kidney failure
 metoclopramide hydrochloride; pharmacokinetics, CAPD, 174
 sucralfate; toxicity, α -luminol overload, deferoxamine therapy, CAPD, 636

L

Labeling
 angiotensin-converting enzyme inhibitors; warnings, risks, pregnancy, 467
 astemizole; warnings, cardiovascular toxicity, 825
 devices; dosage measuring, overdose, 220
 terfenadine; warnings, cardiovascular toxicity, 825
 triazolam; changes, FDA approvals, 467

- Lactase**; lactose intolerance; effects, reduced symptoms, 533
- Lactation**; ciprofloxacin hydrochloride; milk and blood levels, 352
- Lactose intolerance**; lactase; effects, reduced symptoms, 533
- Letters**, 13, 104, 222, 308, 386, 583, 674, 767
- Asthma in children, 386
- Beta-adrenergic agonists in asthma, 13
- Danger of epidural use of ionic contrast media, 105
- Diffuse rash associated with transdermal fentanyl, 222
- Potential interaction between terfenadine and macrolide antibiotics, 675
- Seizures after intraventricular cefazolin administration, 104
- Topical capsaicin for osteoarthritis, 308
- Use of cytomegalovirus immune globulin, 674
- Use of succimer, 387
- Use of surfactant products, 583
- Value of transdermal fentanyl, 584
- Leukemia**; therapy; acute, adult, review, 767
- Lidocaine**
- combination, prilocaine; anesthesia, pain, s.c. injection sites, 347
- diluent; ceftriaxone, reconstitution, concentrated, pediatric, 961
- Liver cirrhosis**
- β blockers; gastrointestinal hemorrhage prophylaxis, 337
- ursodiol; biliary, pruritus therapy, 672
- Liver diseases**; effects; astemizole, terfenadine toxicity, 825
- Lomefloxacin hydrochloride**
- marketing; FDA approvals, 458
- pharmacology; review, 753
- Lung diseases**
- aminophylline; therapy, DUE criteria, 1033
- theophylline; therapy, DUE criteria, 1033
- M**
- Macrolides**
- azithromycin; FDA approvals, 98; marketing delay, Pfizer, 218; pharmacology, 137
- clarithromycin; FDA approvals, 98; pharmacology, 137
- erythromycin; gastroparesis therapy, effects, motilin, 917
- Magnesium sulfate**; eclampsia; and preeclampsia therapy, 236
- Marketing**
- aldesleukin; FDA approvals, 669
- azithromycin; delay, Pfizer, 218; FDA approvals, 98
- cefepodoxime proxiel; FDA approvals, 999
- cefprozil; FDA approvals, 295
- clarithromycin; FDA approvals, 98
- cognition activators; FDA disapprovals, 467
- diphtheria and tetanus toxoids and pertussis vaccines; FDA approvals, 290
- felodipine; FDA approvals, 9
- finasteride; FDA approvals, 825
- flumazenil; FDA approvals, 287
- lomefloxacin hydrochloride; FDA approvals, 458
- nabumetone; FDA approvals, 381
- new drugs; and biologicals, FDA approvals, 1991, 208
- pamidronate disodium; FDA approvals, 220
- pravastatin sodium; FDA approvals, 99
- quinapril hydrochloride; FDA approvals, 220
- sertraline hydrochloride; FDA approvals, 381
- simvastatin; FDA approvals, 290
- temafloxacin hydrochloride; FDA approvals, 381
- ticlopidine hydrochloride; FDA approvals, 99
- zalcitabine; FDA approvals, accelerated drug review policy, 747
- Mechanism of action**
- antibiotics; postantibiotic effect, 865
- azithromycin, 137
- clarithromycin, 137
- idarubicin, 152
- lomefloxacin hydrochloride; review, 753
- sertraline hydrochloride, 381
- sumatriptan succinate; migraine therapy, review, 919
- temafloxacin hydrochloride; review, 753
- ticlopidine hydrochloride; cerebrovascular disorders therapy, review, 603
- Mesalamine**; inflammatory bowel disease; therapy, 514
- Methemoglobinemia**; dapson; toxicity, therapy, 800
- Methotrexate**; pregnancy; ectopic, therapy, 529
- Methylene blue**; and charcoal activated; therapy, dapson toxicity, 800
- Metoclopramide hydrochloride**; pharmacokinetics; peritoneal dialysis, 174
- Metocurine iodide**; use; evaluation, criteria, 435
- Metrolite**; devices; dosage measuring, overdose potential, 220
- Midazolam hydrochloride**; muscle spasticity; therapy, morphine toxicity, 57
- Migraine**
- sumatriptan; therapy, DUE criteria, 972
- sumatriptan succinate; therapy, review, 919
- Misoprostol**; ulcers; therapy, NSAID toxicity, review, 690
- Monoamine oxidase inhibitors**; depression; therapy, geriatrics, 96
- Moricizine**; interactions; implanted cardiac devices, 48
- Morphine sulfate**
- pain; postoperative, intrathecal and i.v. PCA vs. PCA, 958
- patient-controlled analgesia; Baxter Infusor, postoperative pain therapy, 342
- toxicity; muscle spasticity, midazolam therapy, 57
- Mortality**
- β agonists; regular vs. as-needed, asthma therapy, 877
- antiarrhythmic agents; toxicity, 714
- Mouthwashes**; tranexamic acid; hemorrhage prophylaxis, anticoagulant toxicity, dental surgery, 857
- Muscle spasticity**; morphine sulfate; toxicity, midazolam therapy, 57
- N**
- Nabumetone**; marketing; FDA approvals, 381
- Nadolol**; gastrointestinal hemorrhage; prophylaxis, cirrhosis, esophageal varices, 337
- Nausea**
- anesthetics; and vomiting, toxicity, surgery, 965
- ondansetron hydrochloride; and vomiting, therapy, cisplatin toxicity, 1026
- Nebacumab**
- sepsis; antitoxin monoclonal antibodies, therapy, criteria, 255
- use; evaluation, criteria, 257
- Neoplasms**; pamidronate disodium; hypercalcemia therapy, FDA approvals, 220
- News**, 4, 96, 208, 287, 378, 458, 574, 669, 747, 825, 912, 991
- Acellular pertussis vaccine approved by FDA, 290
- Adverse effects prompt withdrawal of temafloxacin, 747
- Benzodiazepine antagonist approved by FDA, 287
- Call for applications to conduct research on patient outcomes associated with pharmaceutical therapy in ambulatory-care setting, 467
- CDC advises on management of persons exposed to multiple-drug-resistant tuberculosis, 991
- Cefepodoxime marketing approved by FDA, 999
- Cefprozil enters oral antibiotic market, 295
- Cognitive enhancers illegal, says FDA, 467
- Depression in elderly is common but undertreated, says expert panel, 96
- Didanosine and foscarnet marketed for use by patients with AIDS, 4
- EPA seeks information on efficacy of sterilants and disinfectants, 295
- Expert panel issues guidelines on asthma management, 295
- False-positive viral antibody test results reported in influenza vaccine recipients, 220
- FDA announces four initiatives for drug approval system, 574
- FDA approves release of recombinant interleukin-2 product, 669
- FDA approves treatment IND protocol for taxol, 912
- FDA seeks changes in benzodiazepine packaging and labeling, 295
- FDA seizes cold sterilizing solution, 220
- FDA warns of overdose risk from dosage cups, 220
- FDA warns quality of undergrowth zalcitabine is poor; Roche expands premarketing access programs, 385
- Federal task force revises recommendations for PCP prophylaxis, 670
- Felodipine marketed as antihypertensive agent, 9
- Finasteride approved for treatment of benign prostatic hyperplasia, 825
- Free drug programs for indigent patients should be more accessible, says Senate committee on aging, 1000
- Guidelines address systemic glucocorticosteroid use for infection management, 295
- HDL testing should be routine part of assessments of coronary heart disease risk, says consensus panel, 378
- Heavy use of inhaled β agonists associated with increased risk of fatal or near-fatal asthma, study shows, 458
- Lomefloxacin reaches U.S. market, 458
- Nabumetone marketed for osteoarthritis, rheumatoid arthritis, 381
- New labeling and patient insert for triazolam approved by FDA, 467
- News Briefs, 9, 103, 221, 296, 385, 467, 576, 670, 750, 829, 912, 1000
- Oral temafloxacin approved for U.S. market, 381
- Pamidronate released for management of hypercalcemia of malignancy, 220
- Pediatrics academy issues new guidelines for acellular pertussis vaccine use, 576
- Pfizer delays marketing azithromycin, 218
- Pravastatin reaches U.S. market, 99
- Quinapril marketed as antihypertensive agent, 220
- Results of ISIS-3 published, 576
- Review of 1991 shows 30 new drugs, several important biologics cleared for marketing, 208
- Sertraline cleared for marketing as antidepressant, 381
- Tacrine made available under treatment IND protocol, 385
- Talley to succeed Zellmer as editor of *AJHP* and *Clinical Pharmacy*, 750
- Terfenadine and astemizole pose cardiovascular risks to certain patients, health professionals warned, 825
- Third HMG-CoA reductase inhibitor marketed for cholesterol reduction, 290
- Three studies examine angiotensin-converting-enzyme-inhibitor prevention of heart failure, 999
- Ticlopidine approved for stroke prevention, 99
- Treatment IND protocol announced for *Pneumocystis carinii* pneumonia, 99
- Two macrolide antimicrobials approved for marketing, 98
- United Kingdom suspends sales of triazolam; FDA to review safety data, 9
- Upcoming Specialty Meetings, 9, 103, 221, 296, 385, 470, 576, 670, 750, 912, 1000
- Warnings about use of angiotensin-converting-enzyme inhibitors in advanced pregnancy strengthened, 467
- Working group issues report on aluminum contamination of parenteral nutrient solutions, 6
- Zalcitabine approved under accelerated drug review policy, 747
- Nimodipine**; cerebrovascular disorders; ischemic stroke therapy, 350
- Nutrition**
- diet; lactose intolerance, lactase effects, reduced symptoms, 533
- parenteral; home therapy, side effects, 543
- O**
- Occult blood**; tests, laboratory; Gastrocult vs. Hemocult, interference, sucralate, 625
- Olsalazine sodium**; inflammatory bowel disease; therapy, 514
- Omeprazole**
- ulcers; therapy, NSAID toxicity, review, 690
- use; evaluation, criteria, 177
- Ondansetron hydrochloride**; pharmacokinetics; therapy, cisplatin toxicity, 1026
- Opiates**; pain; protocols, therapy, 391
- Osteoarthritis**
- nabumetone; therapy, FDA approvals, 381
- oxaprozin; therapy, 591
- Ovarian neoplasms**; taxol; treatment IND, FDA approvals, 912
- Oxaprozin**; arthritis; rheumatoid, and osteoarthritis, therapy, 591
- P**
- Package inserts**; patients; triazolam, changes, FDA approvals, 467
- Paclitaxel**, see **Taxol**
- Pain**
- analgesics; protocols, therapy, 309
- lidocaine, combination, prilocaine; anesthesia, s.c. injection sites, 347
- morphine sulfate; postoperative, Baxter Infusor PCA, 342; postoperative, intrathecal and i.v. PCA vs. PCA alone, 958
- therapy; protocols, 391
- Pamidronate disodium**; marketing; FDA approvals, 220

Annual Index

- Pancuronium bromide**; use; evaluation, criteria, 435
- Parasympatholytic agents**; drug use; evaluation, criteria, therapy, extrapyramidal side effects, 553
- Parenterals, see Injections**
- Paroxetine**; depression; therapy, review, 930
- Patches transdermal**
- fentanyl; adverse reactions, diffuse rash, 222; pain therapy, 22
- scopolamine; hyperemesis gravidarum therapy, 830
- Patient-controlled analgesia**; morphine sulfate; and intrathecal vs. PCA alone, postoperative pain therapy, 958; Baxter Infusor, postoperative pain therapy, 342
- Patients**
- inpatients; amphotericin B, DUE criteria, 809; antiendotoxin monoclonal antibodies, DUE criteria, 257; DUE criteria, therapy, extrapyramidal side effects, 553; omeprazole, DUE criteria, 177; zidovudine, DUE criteria, 63
- outpatients; aminophylline, theophylline, DUE criteria, 1033; DUE criteria, therapy, extrapyramidal side effects, 553; omeprazole, DUE criteria, 177; sumatriptan, DUE criteria, 972; zidovudine, DUE criteria, 63
- Pediatrics**
- amphotericin B; candidiasis therapy, burns, infant, 883
- analgesics and antipyretics; fever therapy, review, 1005
- antibodies; monoclonal antiendotoxin, DUE criteria, 257
- antihistamines; DUE criteria, therapy, extrapyramidal side effects, 553
- antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553
- benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553
- ceftriaxone; i.m., concentrated, pharmacokinetics, toxicity, 961
- didanosine; DUE criteria, 885
- diphtheria and tetanus toxoids and pertussis vaccines; marketing, FDA approvals, 290
- ethosuximide and phenobarbital; clearance, peritoneal dialysis, 1030
- fluconazole; candidiasis therapy, lack, burns, infant, 883
- Haemophilus b* oligosaccharide conjugate vaccines; equivalency, immunogenicity, 332
- Haemophilus b* polysaccharide conjugate vaccines; equivalency, immunogenicity, 332
- neonates; beractant, DUE criteria, 357; ciprofloxacin blood levels, maternal administration, 352; Exosurf Neonatal, DUE criteria, 355; pulmonary surfactant, adult respiratory distress syndrome therapy, 880
- pain; therapy, protocols, infants and neonates, 391
- parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553
- phenobarbital and ethosuximide; clearance, peritoneal dialysis, 1030
- zidovudine; DUE criteria, 63
- Pfizer Pharmaceuticals**; azithromycin; marketing delay, 218
- Pharmacokinetics**
- acetaminophen; fever therapy, pediatrics, review, 1005
- aldesleukin, 669
- anti-infective agents; absorption, intraperitoneal, CAPD, 246
- aspirin; fever therapy, pediatrics, review, 1005
- azithromycin, 98, 137
- cefepodoxime proxiel, 999
- cefprozil, 295
- ceftriaxone; i.m., concentrated, pediatrics, 961
- clarithromycin, 98, 137
- didanosine, 4
- diphtheria and tetanus toxoids and pertussis vaccines; pediatrics, 290
- doxazosin mesylate; review, 415
- felodipine, 9
- finasteride, 825
- flumazenil, 287
- fuscarnet sodium, 4
- ibuprofen; fever therapy, pediatrics, review, 1005
- idarubicin, 152
- γ-interferon; review, 834
- interferon gamma-1b; review, 834
- lomefloxacin hydrochloride, 458; review, 753
- mesalamine, 514
- metoclopramide hydrochloride; peritoneal dialysis, 174
- nabumetone, 381
- olsalazine sodium, 514
- ondansetron hydrochloride; therapy, cisplatin toxicity, 1026
- oxaprozin, 591
- pamidronate disodium, 220
- pravastatin sodium, 99; hypercholesterolemia therapy, review, 677
- quinapril hydrochloride, 220
- serotonin reuptake inhibitors; depression, therapy, review, 930
- sertraline hydrochloride, 381
- simvastatin, 290
- sumatriptan succinate; migraine therapy, review, 919
- temafloxacin hydrochloride, 381; review, 753
- ticlopidine hydrochloride, 99; review, 603
- verapamil hydrochloride; equivalency, intact capsules vs. sprinkled on food, 539
- Pharmacy, institutional, hospital**
- quality assurance; programs, adenosine, DUE criteria, 727; programs, aminophylline, theophylline, DUE criteria, 1033; programs, amphotericin B, DUE criteria, 809; programs, antiendotoxin monoclonal antibodies, DUE criteria, 257; programs, beractant, DUE criteria, 357; programs, didanosine, DUE criteria, 885; programs, DUE criteria, therapy, extrapyramidal side effects, 553; programs, Exosurf Neonatal, DUE criteria, 355; programs, omeprazole, DUE criteria, 177; programs, skeletal muscle relaxants, DUE criteria, 435; programs, sumatriptan DUE criteria, 972; programs, zidovudine, DUE criteria, 63
- Phenobarbital**; and ethosuximide; clearance, peritoneal dialysis, 1030
- Phenylpropanolamine hydrochloride**; toxicity; hypertension, lack, 168
- Phenytoin**; eclampsia; and preeclampsia therapy, 236
- Pipercuronium bromide**; use; evaluation, criteria, 435
- Placental transfer**; scopolamine; transdermal patches, hyperemesis gravidarum therapy, 830
- Plants**; herbs; cognition disorders therapy, FDA disapprovals, 467
- Platelet aggregation inhibitors**
- hyperfibrinogenemia; therapy, 968
- ticlopidine hydrochloride; cerebrovascular disorders therapy, review, 603
- Pneumonia**; 566C80; *P. carinii*, treatment IND, FDA approvals, 99
- Poisoning**; dapsone; therapy, 800
- Polyethylene glycol**; combination, electrolytes; gastric lavage, diabetes mellitus, protocols, 751
- Pravastatin sodium**
- hypercholesterolemia; therapy, review, 677
- marketing; FDA approvals, 99
- Preeclampsia**; therapy, 236
- Pregnancy**
- angiotensin-converting enzyme inhibitors; risks, labeling, warnings, 467
- methotrexate; ectopic, therapy, 529
- scopolamine; hyperemesis gravidarum therapy, transdermal patches, 830
- Prilocaine**; combination, lidocaine; anesthesia, pain, s.c. injection sites, 347
- Product withdrawal**
- azithromycin; Pfizer, marketing delay, 218
- temafloxacin hydrochloride; toxicity, FDA regulations, 747
- tirozolam; United Kingdom, 9
- Prolactin inhibitors**
- amantadine; hyperprolactinemia therapy, psychotropic toxicity, 851
- bromocriptine; hyperprolactinemia therapy, psychotropic toxicity, 851
- Propranolol**; gastrointestinal hemorrhage; prophylaxis, cirrhosis, esophageal varices, 337
- Prostatic hypertrophy**; finasteride; therapy, FDA approvals, 825
- Prothrombin time**
- tetracycline hydrochloride; interactions, warfarin, potentiation, 806
- warfarin sodium; interactions, tetracycline, potentiation, 806
- Protocols**
- adenosine; DUE criteria, 727
- alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; DUE criteria, 355
- American Society of Hospital Pharmacists; antimicrobial prophylaxis, surgery, 483; globulin immune, i.v. therapy, 117
- aminophylline; DUE criteria, 1033
- amphotericin B; bladder irrigation, DUE criteria, 809
- antibodies; monoclonal antiendotoxin, DUE criteria, 257
- antihistamines; DUE criteria, therapy, extrapyramidal side effects, 553
- antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553
- benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553
- beractant; DUE criteria, 357
- didanosine; DUE criteria, 885
- electrolytes, combination, polyethylene glycol; gastric lavage, diabetes mellitus, 751
- 566C80; *P. carinii* pneumonia, treatment IND, FDA approvals, 99
- omeprazole; ulcers, peptic esophagitis, therapy, DUE criteria, 177
- pain; therapy, 309, 391
- parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553
- skeletal muscle relaxants; DUE criteria, 435
- sumatriptan; DUE criteria, 972
- taxol; treatment IND, FDA approvals, 912
- theophylline; DUE criteria, 1033
- zidovudine; DUE criteria, 63
- Pruritus**; ursodiol; therapy, biliary cirrhosis, 672
- Psychotherapeutic agents**
- toxicity; extrapyramidal side effects, therapy, DUE criteria, 553
- toxicity; hyperprolactinemia, therapy, 851
- Pulmonary surfactants**
- alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; adult respiratory distress syndrome therapy, neonate, 880; DUE criteria, 355
- beractant; DUE criteria, 357
- Purchasing**; zalcitabine; quality problems, AIDS buyers groups, 385

Q

Quality assurance; hospital pharmacy; programs, adenosine, DUE criteria, 727; programs, aminophylline, theophylline, DUE criteria, 1033; programs, amphotericin B, DUE criteria, 809; programs, antiendotoxin monoclonal antibodies, DUE criteria, 257; programs, beractant, DUE criteria, 357; programs, didanosine, DUE criteria, 885; programs, DUE criteria, therapy, extrapyramidal side effects, 553; programs, Exosurf Neonatal, DUE criteria, 355; programs, omeprazole, DUE criteria, 177; programs, skeletal muscle relaxants, DUE criteria, 435; programs, sumatriptan DUE criteria, 972; programs, zidovudine, DUE criteria, 63

Quinapril hydrochloride; marketing; FDA approvals, 220

Quinolones

ciprofloxacin hydrochloride; blood and milk levels, 352

lomefloxacin hydrochloride; FDA approvals, 458; pharmacology, review, 753

temafloxacin hydrochloride; FDA approvals, 381; pharmacology, review, 753; product withdrawal, toxicity, FDA regulations, 747

R

Rabies; immunization; vaccines, human rabies immune globulin, 37

Rabies immune globulin; immunization, 37

Rabies vaccines; human diploid cell; immunization, 37

Rational therapy; antiarrhythmic agents, 714

Regulations

Food and Drug Administration; astemizole, terfenadine, warning labels, cardiovascular toxicity, 825; cognition activator marketing, 467; zalcitabine, quality problems, premarketing access, 385

labeling; ACE inhibitors, warnings, risks, pregnancy, 467

new-drug applications; approvals, changes, FDA processing, 574

temafloxacin hydrochloride; product withdrawal, FDA, 747

Respiratory distress syndrome

alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; adult, therapy, neonate, 880; therapy, DUE criteria, 355

beractant; therapy, DUE criteria, 357

Respiratory smooth-muscle relaxants

aminophylline; availability, enteral administration, 428; DUE criteria, 1033

theophylline; DUE criteria, 1033

Respiratory tract infections

azithromycin; therapy, FDA approvals, 98; therapy, marketing delay, Pfizer, 218

clarithromycin; therapy, FDA approvals, 98

Reye's syndrome; aspirin; toxicity, fever therapy, pediatrics, 1005

Roentgenographic agents; ionic; epidural, toxicity, inadvertent intrathecal injection, 105

S

- Sales:** triazolam; product withdrawal, United Kingdom, 9
- Saline, see Sodium chloride**
- Scopolamine:** hyperemesis gravidarum; transdermal patches, 830
- Seizures:** cefazolin sodium; toxicity, intraventricular injections, 104
- Self-study Materials:** *Concepts in Oncology Therapeutics, A Self-Instructional Course*, 568
- Sepsis:** antibodies; antiendotoxin monoclonal, therapy, 223; antiendotoxin monoclonal, therapy, criteria, 255; antiendotoxin monoclonal, therapy, DUE criteria, 257
- Serotonin agonists**
sumatriptan; DUE criteria, 972
sumatriptan succinate; migraine therapy, review, 919
- Sertraline hydrochloride**
depression; therapy, review, 930
marketing; FDA approvals, 381
- Shock:** antibodies; septic, antiendotoxin monoclonal, therapy, 223
- Simvastatin:** marketing; FDA approvals, 290
- Skeletal muscle relaxants**
atracurium besylate; DUE criteria, 435
doxacurium chloride; DUE criteria, 435
metocurine iodide; DUE criteria, 435
midazolam hydrochloride; muscle spasticity therapy, morphine toxicity, 57
pancuronium bromide; DUE criteria, 435
pilocurium bromide; DUE criteria, 435
tubocurarine chloride; DUE criteria, 435
vecuronium bromide; DUE criteria, 435
- Skin diseases**
azithromycin; therapy, FDA approvals, 98
clarithromycin; FDA approvals, 98
- Sodium chloride:** comparison, heparin; i.v. lock flushing, 797
- Sucralate**
interference; occult blood tests, Gastrocult vs. Hemocult, 625
toxicity; aluminum overload, deferoxamine therapy, CAPD, 636
- Sumatriptan:** use; evaluation, criteria, 972
- Sumatriptan succinate:** migraine; therapy, review, 919
- Surgery**
anesthetics; abdominal, toxicity, nausea and vomiting, 965
anti-infective agents; prophylaxis, ASHP protocols, 483
dental; hemorrhage prophylaxis, anticoagulant toxicity, 857
protocols; pain therapy, 309, 391
- Sustained-action medications**
calcium antagonists; therapy, improved patient compliance, 549
verapamil hydrochloride; intact capsules vs. sprinkled on food, pharmacokinetics, 539
- Sympatholytic agents**
 β blockers; hyperfibrinogenemia therapy, 968
nadolol; gastrointestinal hemorrhage, prophylaxis, cirrhosis, esophageal varices, 337
propranolol; gastrointestinal hemorrhage, prophylaxis, cirrhosis, esophageal varices, 337
- Sympathomimetic agents**
 β agonists; aerosols, dosage schedules, asthma therapy, 877; asthma therapy, controversies, 13
phenylpropanolamine hydrochloride; toxicity, hypertension, lack, 168

T

- Tachycardia:** adenosine; paroxysmal supraventricular, therapy, DUE criteria, 727
- Taxol:** ovarian neoplasms; treatment IND, FDA approvals, 912
- Tefazolin hydrochloride**
marketing; FDA approvals, 381
pharmacology; review, 753
product withdrawal; toxicity, FDA regulations, 747
- Teratogenicity**
angiotensin-converting enzyme inhibitors; pregnancy, labeling, warnings, 467
scopolamine; placental transfer, hyperemesis gravidarum transdermal therapy, 830
- Terfenadine:** toxicity; cardiovascular, labeling, warnings, 825
- Tests, laboratory**
cholesterol; and HDL monitoring, coronary disease, 378

- occult blood; Gastrocult vs. Hemocult, interference, sucralate, 625
- Tetracycline hydrochloride:** interactions; warfarin, potentiation, prothrombin time, 806
- Tetracyclines:** tetracycline hydrochloride; interactions, warfarin, potentiation, prothrombin time, 806
- Theophylline**
blood levels; aminophylline availability, enteral administration, 428
use; evaluation, criteria, 1033
- Therapy Consultation:** 672, 751, 830, 917
- Diabetes control during bowel cleansing with PEG-electrolyte solution,** 751
- Erythromycin, motilin, and gastroparesis,** 917
- Transdermal scopolamine for hyperemesis gravidarum,** 830
- Use of ursodiol in a patient with biliary cirrhosis,** 672
- Thrombocytopenia;** heparin; toxicity, i.v. lock flushing, 797
- Thromboembolism;** heparin; toxicity, i.v. lock flushing, 797
- Ticlopidine hydrochloride**
cerebrovascular disorders; therapy, review, 603
marketing; FDA approvals, 99
- Topical preparations**
fentanyl; transdermal patches, pain therapy, 22
lidocaine, combination, prilocaline; creams, anesthesia, pain, s.c. injection sites, 347
- Toxicity**
acetaminophen; fever therapy, pediatrics, review, 1005
adenosine; DUE criteria, 727
 β agonists; regular vs. as-needed, asthma, 877
alcohols, cetyl, combination, colfosceril palmitate, tyloxapol; DUE criteria, 355
aldesleukin, 669
aminophylline; DUE criteria, 1033
amphotericin B; DUE criteria, 809
anesthetics; nausea and vomiting, abdominal surgery, 965
angiotensin-converting enzyme inhibitors; pregnancy, labeling, warnings, 467
antiarrhythmic agents, 714; interactions, implanted cardiac devices, 48
antibodies; monoclonal antiendotoxin, DUE criteria, 257
anticoagulants; hemorrhage, dental surgery, 857
anticholinergics; DUE criteria, therapy, extrapyramidal side effects, 553
anti-infective agents; postantibiotic effect, factors, 865
anti-inflammatory agents; nonsteroidal, ulcers, therapy, review, 690
antiparkinson agents; DUE criteria, therapy, extrapyramidal side effects, 553
aspirin; Reye's syndrome, fever therapy, pediatrics, 1005
astemizole; cardiovascular, labeling, warnings, 825
azithromycin; side effects, 98, 137; side effects, marketing delay, Pfizer, 218
benzodiazepines; DUE criteria, therapy, extrapyramidal side effects, 553; overdose, flumazenil therapy, 287
beractant; DUE criteria, 357
 β blockers; side effects, gastrointestinal hemorrhage prophylaxis, 337
calcium antagonists; side effects, 549
cefazolin sodium; seizures, intraventricular injections, 104
cefprozil, 295
ceftriaxone; side effects, lack, i.m., concentrated, pediatrics, 961
cisplatin; ondansetron therapy, pharmacokinetics, 1026
clarithromycin; side effects, 98, 137
dapson; hemolytic anemia, methemoglobinemia, therapy, 800
didanosine, 4; DUE criteria, 885
diphtheria and tetanus toxoids and pertussis vaccines; side effects, pediatrics, 290
doxazosin mesylate; side effects, 415
drugs; endocrine disorders, HIV infections, therapy, 705; measuring cups, spoons, droppers, dosing problems, 220
felodipine, 9
fentanyl; transdermal, side effects, 22
finasteride, 825
flumazenil, 287
foscarnet sodium, 4
ganciclovir; liver, cytomegalic inclusion disease therapy, AIDS, 432
globulin immune; reconstitution, dextrose vs. water for injection, lack, 628; side effects, concentrated injections, 1022
Haemophilus b oligosaccharide conjugate vaccines;

- side effects, pediatrics, 332
- Haemophilus b* polysaccharide conjugate vaccines; side effects, pediatrics, 332
- heparin; flushes, thrombocytopenia, thromboembolism, 797
- ibuprofen; fever therapy, pediatrics, review, 1005
- idarubicin; side effects, 152
- injections; pain, lidocaine-prilocaine topical anesthesia, 347
- γ -interferon; side effects, review, 834
- interferon gamma-1b; side effects, review, 834
- lomefloxacin hydrochloride; side effects, 458, 753
- mesalamine; side effects, 514
- methotrexate; side effects, ectopic pregnancy therapy, 529
- morphine sulfate; Baxter Infusor, PCA, postoperative pain therapy, 342; muscle spasticity, midazolam therapy, 57; side effects, intrathecal and i.v. PCA vs. PCA alone, 958
- nabumetone, 381
- nutrition; parenteral, home therapy, 543
- olsalazine sodium; side effects, 514
- omeprazole; side effects, DUE criteria, 177
- oxaprozin; side effects, 591
- pamidronate disodium, 220
- parasympatholytic agents; DUE criteria, therapy, extrapyramidal side effects, 553
- phenylpropanolamine hydrochloride; hypertension, lack, 168
- pravastatin sodium; side effects, 99; side effects, hypercholesterolemia therapy, review, 677
- psychotherapeutic agents; extrapyramidal side effects, DUE criteria, 553; hyperprolactinemia, therapy, 851
- quinapril hydrochloride, 220
- roentgenographic agents; ionic, inadvertent intrathecal injection, 105
- scopolamine; placental transfer, hyperemesis gravidarum transdermal therapy, 830
- serotonin reuptake inhibitors; side effects, depression therapy, review, 930
- sertraline hydrochloride, 381
- simvastatin, 290
- skeletal muscle relaxants; DUE criteria, 435
- sucralate; aluminum overload, deferoxamine therapy, CAPD, 636
- sumatriptan; DUE criteria, 972
- sumatriptan succinate; side effects, migraine therapy, review, 919
- temafloxacin hydrochloride, 381; side effects, 753
- terfenadine; cardiovascular, labeling, warnings, 825
- tetracycline hydrochloride; interactions, warfarin, potentiation, prothrombin time, 806
- theophylline; DUE criteria, 1033
- ticlopidine hydrochloride; side effects, 99; side effects, review, 603
- triazolam; side effects, product withdrawal, United Kingdom, 9
- verapamil hydrochloride; side effects, lack, intact capsules vs. sprinkled on food, 539
- warfarin sodium; interactions, tetracycline, potentiation, prothrombin time, 806; intramural hematoma of the small intestine, 632
- zalcitabine, 747
- zidovudine; DUE criteria, 63
- Tranexamic acid;** hemorrhage; prophylaxis, dental surgery, anticoagulant toxicity, 857
- Transplantation;** bone marrow; adult acute leukemia, therapy, review, 767; globulin immune, concentrated injections, toxicity, 1022
- Triazolam**
labeling; changes, FDA approvals, 467
product withdrawal; United Kingdom, 9
- Tubocurarine chloride:** use; evaluation, criteria, 435
- Tyloxapol;** combination, alcohols, cetyl, colfosceril palmitate; adult respiratory distress syndrome therapy, neonate, 880; use evaluation criteria, 355

U

- Ulcers**
anti-inflammatory agents; nonsteroidal, toxicity, review, 690
omeprazole; duodenal, gastric, therapy, DUE criteria, 177
- United Kingdom:** triazolam; product withdrawal, 9
- Urinary tract infections;** amphotericin B; therapy, DUE criteria, 809
- Ursodiol;** pruritus; therapy, biliary cirrhosis, 672

Annual Index

V

Vaccines

- diphtheria and tetanus toxoids and pertussis; marketing, FDA approvals, 290
- Haemophilus b* oligosaccharide conjugate; equivalency, immunogenicity, pediatrics, 332
- Haemophilus b* polysaccharide conjugate; equivalency, immunogenicity, pediatrics, 332
- rabies; human diploid cell, immunization, 37
- Vancomycin**; intraperitoneal; absorption, CAPD, 246
- Vasodilating agents**; hyperfibrinogenemia; therapy, 968
- Vecuronium bromide**; use; evaluation, criteria, 435
- Vehicles**
 - dextrose, comparison, water for injection; globulin immune reconstitution, toxicity, 628
 - water for injection, comparison, dextrose; globulin immune reconstitution, toxicity, 628
- Verapamil hydrochloride**; pharmacokinetics; equivalency, intact capsules vs. sprinkled on food, 539

- Vitamins**; marketing; cognition disorders therapy, FDA disapprovals, 467
- Volume of distribution**, see **Drugs**, body distribution
- Vomiting**
 - anesthetics; and nausea, toxicity, surgery, 965
 - ondansetron hydrochloride; and nausea, therapy, cisplatin toxicity, 1026

W

Warfarin sodium

- interactions; tetracycline, potentiation, prothrombin time, 806
- toxicity; intramural hematoma of the small intestine, 632
- Water for injection**; comparison, dextrose; globulin immune reconstitution, toxicity, 628
- Weight**; patients; nausea and vomiting, anesthetics toxicity, surgery, 965
- Wounds and injuries**; protocols; pain therapy, 309, 391

X

Xomen-ES

- sepsis; antiendotoxin monoclonal antibodies, therapy, 223; antiendotoxin monoclonal antibodies, therapy, criteria, 255
- use; evaluation, criteria, 257

Z

Zalcitabine

- marketing; FDA approvals, accelerated drug review policy, 747
- purchasing; AIDS buyers groups, quality problems, 385
- Zidovudine**
 - and zalcitabine; HIV infections, combined therapy, 747
 - use; evaluation, criteria, 63

Author Index

A

- Acosta, Mark A. see Bradley, John S., 961
- Adams, Margaret A. see Kozloski, Gary D., 539
- Agency for Health Care Policy and Research Acute pain management: operative or medical procedures and trauma, part 1, 309; part 2, 391
- Anderson, Douglas C. Jr. see Sagraves, Rosalie, 830
- ASHP Commission on Therapeutics ASHP therapeutic guidelines for intravenous immune globulin, 117
- ASHP Commission on Therapeutics ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery, 483
- Avent, Minyon L. Warfarin-induced intramural hematoma of the small intestine, 632

B

- Babamoto, Kenneth S. Doxazosin: a new α_1 -adrenergic antagonist, 415
- Bagwell, J. Todd see Martin, Emory S. III, 104
- Baillie, George R. see Figge, Helen L., 432
- Banner, William Jr. Use of succimer (letter), 388
- Barone, Joseph A. see Frenia, Maureen L., 37
- Barriere, Steven L. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies, 223
- Barton, Terri L. see Chan, C. Y., Jennifer, 880
- Batra, Kumar K. see Marquardt, Eric D., 1030
- Bauman, Jerry L. see Tworek, Deborah A., 48
- Bay, William see Gora, Mary Lea, 174
- Benson, John M. Nausea and vomiting after abdominal surgery, 965
- Bernstein, Linda R. see Herfindal, Eric T., 543
- Bezarr, Edward R. see Wermeling, Daniel P., 342
- Bhatt-Mehta, Varsha Criteria for use of colfosceril (Exosurf Neonatal) in neonates, 355
- Birmingham, William E. see Littrell, Robert A., 57
- Bjornson, Darrel C. see Cortese, Linda M., 675, 885
- Blake, Kathryn V. see Hill, Malcolm R., 877
- Bolinger, Ann M. Recombinant interferon gamma for treatment of chronic granulomatous disease and other disorders, 834
- Boucher, Bradley A. see Wermeling, Daniel P., 342
- Bowden, Talmadge A. Jr. see Benson, John M., 965
- Bradley, John S. Pharmacokinetics and safety of intramuscular injection of concentrated ceftriaxone in children, 961
- Briceland, Laurie L. see Figge, Helen L., 432
- Briggs, Gerald G. see Wermeling, Daniel P., 342
- Brocovich, Joseph M. see Etzel, Joseph V., 705
- Bush-Veith, Stacie see Martin, Emory S. III, 104

C

- Calis, Karim Anton Transdermally administered fentanyl for pain management, 22
- Calis, Karim A. see also Kohler, David R., 584
- Calis, Karim Anton see also Yurkowski, Peter J., 917
- Canaday, Bruce R. see Avent, Minyon L., 632

- Cantral, Kimberly A. see Jungnickel, Paul W., 677
- Capparelli, Edmund V. New calcium-channel blockers: improved therapy? 549
- Cersosimo, Robert J. Idarubicin: an anthracycline antineoplastic agent, 152
- Chan, C. Y. Jennifer Colfosceril in an infant with adult respiratory distress syndrome, 880
- Chandler, Mary H. H. see Parr, Michael D., 1026
- Chin, Barbara see Marquardt, Eric D., 1030
- Coleman, Cathy L. see Benson, John M., 965
- Compogianis, Lisa S. see Bradley, John S., 961
- Coonce, Shannon L. Beta-adrenergic agonists in asthma (letter), 14
- Coonce, Shannon L. see also Simon, Pamela A., 387
- Corso, Diane M. see Calis, Karim Anton, 22
- Corso, Diane M. see also Kohler, David R., 584
- Cortese, Linda M. Criteria for use of didanosine in adult and pediatric patients, 885
- Cortese, Linda M. Potential interaction between terfenadine and macrolide antibiotics (letter), 675

D

- Danos, Erica A. Apparent potentiation of warfarin activity by tetracycline, 806
- Danziger, Larry H. see Piscitelli, Stephen C., 137
- Darbinian, Jeanne A. see Herfindal, Eric T., 543
- D'Elia, John A. see Min, David I., 636
- De Vito, Joseph M. see Kozloski, Gary D., 539
- DeVane, C. Lindsay Book review, 277
- DilPiro, Joseph T. see Benson, John M., 965
- DilPiro, Joseph T. see also Hardin, Thomas C., 255
- Donnelly, Andrew J. Criteria for use of pancuronium bromide, vecuronium bromide, atracurium besylate, tubocurarine chloride, metocurine iodide, pipecuronium bromide, and doxacurium chloride in adults, 435
- Donnigan, D. Deane see Benson, John M., 965
- Dwral-Klein, Laureen A. Antipyretic therapy in the febrile child, 1005

E

- Ebert, Steven C. Characterization of the postantibiotic effect, 876
- Elder, Cheryl A. β -Adrenergic antagonists for primary prevention of gastrointestinal hemorrhage in patients with cirrhosis and esophageal varices, 337
- Ernst, Edzard Lowering the plasma fibrinogen concentration with drugs, 968
- Ernst, Edzard Treating ischemic stroke: is nimodipine the answer? 350
- Erstad, Brian L. Dapsone-induced methemoglobinemia and hemolytic anemia, 800
- Etzel, Joseph V. Endocrine complications associated with human immunodeficiency virus infection, 705
- Ezell, Jeanne R. see Marken, Patricia A., 553
- Ezzi, Marilyn see Tworek, Deborah A., 48

F

- Fankhauser, Martha P. Book review, 655
- Figge, Helen L. Possible ganciclovir-induced hepatotoxicity in patients with AIDS, 432
- Fisher, Joseph N. see Marken, Patricia A., 851
- Flynn, Patrice L. Topical capsaicin for osteoarthritis (letter), 308
- Foster, Thomas S. see Wermeling, Daniel P., 342
- Frenia, Maureen L. Features and treatment of rabies, 37

G

- Gabbe, Steven G. see Gardner, Debra K., 352
- Gales, Barry J. see Segars, Larry W., 514
- Gardner, Debra K. Simultaneous concentrations of ciprofloxacin in breast milk and in serum in mother and breast-fed infant, 352
- Garrelts, James C. White clot syndrome and thrombocytopenia: reasons to abandon heparin i.v. lock flush solution, 797
- Golembiewski, Julie A. see Donnelly, Andrew J., 435
- Goodwin, S. Diane Criteria for use of zidovudine in adult and pediatric inpatients and outpatients, 63
- Gora, Mary Lea Pharmacokinetics of intraperitoneal metoclopramide in a patient with renal failure, 174
- Greene, Stan A. see Wermeling, Daniel P., 342
- Grimley, Sara R. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors, 930
- Guglielmo, B. Joseph see Barriere, Steven L., 223

H

- Haas, Curtis E. Book review, 565
- Hardin, Thomas C. Who should receive antiendotoxin monoclonal antibody therapy? (editorial), 255
- Harter, Chris see Gardner, Debra K., 352
- Haykal, Radwan F. see Marken, Patricia A., 851
- Healy, Daniel P. Book review, 900
- Hecker, Earl T. see Wetmore, Robert W., 958
- Henderson, Lisa M. see Parr, Michael D., 1026
- Herfindal, Eric T. Complications of home parenteral nutrition, 543
- Herzfeld, Jeff see Nee, Chris, 13
- Hill, Malcolm R. Regularly scheduled versus as-needed use of inhaled β agonists in the treatment of asthma, 877
- Hirokawa, William T. see Babamoto, Kenneth S., 415
- Hirsch, Jan D. see Benson, John M., 965
- Hogue, Valerie W. see Herfindal, Eric T., 543
- Holman, Jonathan S. Influence of succalfate on the detection of occult blood in simulated gastric fluid by two screening tests, 625
- Holmes, Gregory B. see Kozloski, Gary D., 539
- Hsu, Van Doren Criteria for use of sumatriptan in adult inpatients and outpatients, 922
- Hsu, Van Doren Sumatriptan: a new drug for vascular headache, 919
- Huber, Steven see Ippoliti, Cindy, 1022
- Hunt, Thomas L. see Kozloski, Gary D., 539

I

- Ignoffo, Robert J.** Self-study materials review, 568
Ippoliti, Cindy Toxicity of rapidly infused concentrated intravenous immune globulin, 1022
Ishisaka, Denis Y. see Marquardt, Eric D., 1030
Ito, Matthew K. Ticlopidine: a new platelet aggregation inhibitor, 603

J

- Jacobson, Pamela A.** see Montgomery, Patricia A., 809
Jann, Michael W. see Grimsley, Sara R., 930
Johnson, Jerry B. see Kozloski, Gary D., 539
Jones, Daniel W. see Sands, Charles D., 168
Joubert, Dennis W. Value of transdermal fentanyl (letter), 584
Jung, Kyung M. see Sands, Charles D., 168
Jungnickel, Paul W. Pravastatin: a new drug for the treatment of hypercholesterolemia, 677

K

- Kalt, Mark A.** see Wetmore, Robert W., 958
Kane, Bud J. Book review, 901
Kennedy, L. Douglas see Littrell, Robert A., 57
Kim, Hyun Jong see Sands, Charles D., 168
Kohler, David R. Value of transdermal fentanyl (letter), 584
Kohler, David R. see also Calis, Karim Anton, 22
Koren, Gideon see Taddio, Anna, 347
Korones, Sheldon B. see Prevost, Rebecca Rogers, 357
Kowalsky, Steven F. see Figge, Helen L., 432
Kozloski, Gary D. Bioequivalence of verapamil hydrochloride extended-release pellet-filled capsules when opened and sprinkled on food and when swallowed intact, 539
Kuhn, John G. see Kane, Bud J., 901

L

- Lafin, Suzanne M.** see Frenia, Maureen L., 37
Lajoie, Caroline Criteria for use of omeprazole in adult patients and outpatients, 177
Leak, W. David see Littrell, Robert A., 57
Lee, Marisa L. see Ito, Matthew K., 603
Lehman, Mark E. see Wermeling, Daniel P., 342
Lindley, Celeste Book review, 92
Ling, Frank W. see Prevost, Rebecca Rogers, 529
Littrell, Robert A. Muscle spasms associated with intrathecal morphine therapy: Treatment with midazolam, 57

M

- MacDonald, John S.** see Parr, Michael D., 1026
Maloley, Pierre A. see Jungnickel, Paul W., 677
Mann, Katherine V. Use of succimer (letter), 388
Marcus, Steven M. Use of succimer (letter), 387
Marken, Patricia A. Criteria for use of agents for extrapyramidal adverse effects in adult, adolescent, and child inpatients and outpatients, 553
Marken, Patricia A. Management of psychotropic-induced hyperprolactinemia, 851
Marquardt, Eric D. Removal of ethosuximide and phenobarbital by peritoneal dialysis in a child, 1030
Martin, Emory S. III Danger of epidural use of ionic contrast media (letter), 105
Martin, Emory S. III Seizures after intraventricular ceftazolin administration (letter), 104
Mason, Nancy A. see O'Brien, Maureen A., 246
Mauro, Laurie S. see Mauro, Vincent F., 897
Mauro, Vincent F. Book review, 897
McCauley, Dayna L. Treatment of adult acute leukemia, 767
McCollam, Patrick L. see Morales, Enid, 727
McCombs, Janet Treatment of preeclampsia and eclampsia, 236
McIntyre, William J. see Parr, Michael D., 1026
McMahon, Teresa Diabetes control during bowel cleansing with PEG-electrolyte solution (Therapy Consultation), 751
Miller, Donald R. Treatment of nonsteroidal anti-inflammatory drug-induced gastropathy, 690
Miller, Kenneth B. Safety and tolerability of an intravenous immune globulin at various concentrations in

- 5% dextrose injection or sterile water for injection, 628
Miller, Lucinda G. Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug, 591
Min, David I. Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine, 636
Mirro, Robert see Prevost, Rebecca Rogers, 357
Montgomery, Patricia A. Criteria for use of amphotericin B bladder irrigation in adult inpatients, 809
Morales, Enid Criteria for use of adenosine in adults with paroxysmal supraventricular tachycardia, 727
Mowatt-Larsen, Christine A. Working group issues report on aluminum contamination of parenteral nutrient solutions (News), 6
Murphy, Christine M. see Coonce, Shannon L., 14
Murphy, Christine M. see also Simon, Pamela A., 387
Murray, William E. see Bradley, John S., 961

N

- Nazari, José** see Tworek, Deborah A., 48
Nee, Chris Beta-adrenergic agonists in asthma (letter), 13
Nix, David E. see Symonds, William T., 753

O

- O'Brien, Maureen A.** Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis, 246

P

- Parr, Michael D.** Pharmacokinetics of ondansetron in patients receiving cisplatin therapy, 1026
Patterson, Larry E. Book review, 901
Phelps, Stephanie J. see Drwal-Klein, Lauren A., 1005
Phillips, Marjorie Shaw Criteria for use of theophylline (aminophylline) in inpatients and outpatients with pulmonary disease, 1033
Pickworth, Kerry K. Long-term dobutamine therapy for refractory congestive heart failure, 618
Pinson, Julianne B. New considerations for *Haemophilus influenzae* type b vaccination, 332
Piscitelli, Stephen C. Clarithromycin and azithromycin: new macrolide antibiotics, 137
Prevost, Rebecca Rogers Criteria for use of beractant (Survanta) in neonates, 357
Prevost, Rebecca Rogers Methotrexate for treatment of unruptured ectopic pregnancy, 529

R

- Rasch, Deborah K.** see Chan, C. Y. Jennifer, 880
Reitberg, Donald P. see Sanders, Steven W., 533
Renger, Harvey Jr. see Martin, Emory S. III, 104
Restino, Maryann S. Reynolds see Elder, Cheryl A., 337
Robieux, Isabelle see Taddio, Anna, 347
Roldvold, Keith A. see Piscitelli, Stephen C., 137
Ruck, Bruce see Marcus, Steven M., 387

S

- Sagraves, Rosalie** Transdermal scopolamine for hyperemesis gravidarum (Therapy Consultation), 830
Sahn, Steven A. see Shalansky, Karen F., 428
Sanders, Steven W. Effect of a single dose of lactase on symptoms and expired hydrogen after lactose challenge in lactose-intolerant subjects, 533
Sands, Charles D. Effect of phenylpropanolamine hydrochloride on blood pressure in Korean patients with hypertension controlled by hydrochlorothiazide, 168
Sawyer, William T. see Avent, Minyon L., 632
Schneken, David P. see Miller, Kenneth B., 628
Schoenbrun, Karen J. Book review, 373
Schumacher, Robert E. see Bhatt-Mehta, Varsha, 355
Segars, Larry W. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease, 514
Seifert, Charles F. see Vondracek, Thomas G., 672
Seth, Shiv see Gora, Mary Lea, 174
Shalansky, Karen F. Absolute bioavailability of aminophylline liquid administered enterally in adults re-

- quiring mechanical ventilation, 428
Shepherd, Michele F. Criteria for use of antiendotoxin monoclonal antibodies (HA-1A and E5) in adult and pediatric inpatients, 257
Shields, Brenda see Gora, Mary Lea, 174
Shipp, Kenneth W. see Goodwin, S. Diane, 63
Shwed, Jill A. see Holman, Jonathan S., 625
Simon, Pamela A. Asthma in children (letter), 387
Simon, Pamela A. see also Coonce, Shannon L., 14
Skupski, Richard see Donnelly, Andrew J., 435
Slimowitz, Richard Book review, 565
Smith, Alden R. see Ito, Matthew K., 603
Snyderman, David R. Use of cytomegalovirus immune globulin (letter), 674
Spivey, J. Michael The postantibiotic effect, 865
Stanfield, Johnny A. see Benson, John M., 965
Stegman, Mary see Stoukides, Cheryl A., 222
Stoukides, Cheryl A. Diffuse rash associated with transdermal fentanyl (letter), 222
Stovall, Thomas G. see Prevost, Rebecca Rogers, 529
Sybert, John W. see Wetmore, Robert W., 958
Symonds, William T. Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials, 753

T

- Taddio, Anna** Effect of lidocaine-prilocaine cream on pain from subcutaneous injection, 347
Taeubel, Mary A. see Bolinger, Ann M., 834
Tisdale, James E. Are antiarrhythmic drugs obsolete? 714
Tisdale, James E. Book review, 277
Tolman, Keith G. see Sanders, Steven W., 533
Torre, Michael see Etzel, Joseph V., 705
Travers, John D. see Mann, Katherine V., 388
Tsu, Gloria L. see Bradley, John S., 961
Tweeddale, Martin G. see Shalansky, Karen F., 428
Tworek, Deborah A. Interference by antiarrhythmic agents with function of electrical cardiac devices, 48

U

- Ustad, Cristina** see Shalansky, Karen F., 428

V

- Vance-Bryan, Kyle** Book review, 742
Vaughan, Leigh M. see Shalansky, Karen F., 428
Visconti, James A. see Gora, Mary Lea, 174
Vondracek, Thomas G. Use of ursodiol in a patient with biliary cirrhosis (Therapy Consultation), 672

W

- Wasserman, Richard L.** see Miller, Kenneth B., 628
Weart, C. Wayne see Pinson, Julianne B., 332
Webb, Charles R. see Tisdale, James E., 714
Weibert, Robert T. Oral anticoagulant therapy in patients undergoing dental surgery, 857
Wermeling, Daniel P. Multicenter evaluation of a patient-controlled analgesia device for the treatment of postoperative pain, 342
West, Dennis see Flynn, Patrice L., 308
Wetmore, Robert W. Intrathecal administration of morphine followed by patient-controlled intravenous administration for postoperative analgesia, 958
Williams, Dennis M. Asthma in children (letter), 386
Williams, Loretta Ann see Ippoliti, Cindy, 1022
Wilson, Dean C. Fluconazole failure in a child with burns and candidemia, 883
Wojtynek, Jeffrey E. see Donnelly, Andrew J., 435
Wong, Alvin F. see Herfindal, Eric T., 543
Woster, Patricia S. see Montgomery, Patricia A., 809

Y

- Yurkowski, Peter J.** Erythromycin, motilin, and gastroparesis (Therapy Consultation), 917

Z

- Zola, Elizabeth M.** Use of surfactant products (letter), 583